[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Henri Duffaut - Avignon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":144},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,67,95,119],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100626293","ultrasound-estimation-of-fetal-macrosomia-at-term-diagnostic-accuracy-within-24-hours-of-delivery-100626293",false,"NCT07433751","Ultrasound Estimation of Fetal Macrosomia at Term: Diagnostic Accuracy Within 24 Hours of Delivery","ECHO-MACRO : Ultrasound Estimation of Fetal Macrosomia at Term: Diagnostic Accuracy Within 24 Hours of Delivery","ECHO-MACRO","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* Patient with suspected fetal macrosomia above the 95th percentile, or above the 90th percentile in the case of maternal diabetes, according to Hadlock's formula and WHO charts, during the third-trimester ultrasound (between 32 and 34 weeks of amenorrhea).\n* Female patient presenting for a follow-up ultrasound at 36 ± 1 weeks of amenorrhea due to suspected macrosomia.\n* Singleton pregnancy.\n\nExclusion Criteria:\n\n* Fetal weight estimation at 36 ± 1 weeks of amenorrhea and macrosomia assessment performed outside of the hospital.\n* Patient with uncertain gestational age.\n* Patient with a multiple pregnancy\n* Presence of detectable morphological or chromosomal abnormalities.",true,"FEMALE","18 Years",{"count":21,"type":22},285,"ESTIMATED","INTERVENTIONAL",[25],"NA","Obstetric ultrasonography is now an essential tool for monitoring pregnancy. In France, three ultrasounds are recommended during a singleton pregnancy (at 12, 22, and 32 weeks of amenorrhea) to improve maternal and neonatal care. Among the parameters studied, fetal weight estimation allows for the assessment of fetal growth and the detection of certain conditions such as intrauterine growth restriction or macrosomia.\n\nFetal weight estimation is based primarily on the Hadlock formula, which combines several biometric measurements (head circumference, abdominal circumference, and femur length). This estimate has a margin of error of 6 to 10% compared to birth weight, which is still accurate enough to guide important medical decisions, such as inducing labor or performing a cesarean section. However, an estimation error can have negative consequences for both mother and child.\n\nFetal macrosomia is defined as a birth weight greater than or equal to 4000 g. It affects approximately 5 to 10% of pregnancies. Screening is mainly based on ultrasound, particularly in the second and third trimesters.\n\nMacrosomia is associated with an increased risk of complications for the mother (cesarean section, postpartum hemorrhage, or deep vein thrombosis) and the child (shoulder dystocia, fractures, brachial plexus palsy, or neonatal asphyxia). These risks are increased in cases of macrosomia in the context of maternal diabetes.\n\nWithin the gynecology-obstetrics department, physicians use the protocole of macrosomia screening described in the DAME trial. If macrosomia is suspected an additional ultrasound is performed at around 36 weeks of amenorrhea. The Hadlock formula is used to estimate fetal weight. The ultrasound criteria for suspecting macrosomia are an estimated fetal weight above the 95th percentile (90th percentile in cases of maternal diabetes) according to WHO curves. In these cases, induction is offered between 38 and 39 weeks of amenorrhea, if the cervix is favorable. A cesarean section is offered to the patient if the estimated fetal weight is greater than 5000 g in the absence of diabetes and greater than 4500 g in cases of associated diabetes.\n\nNevertheless, the probability of a child being born macrosomic after ultrasound suspicion is between 17% and 80% on average, and 53% in our center. Although beneficial in the context of macrosomia, the effects of induced labor or cesarean delivery are not insignificant for the mother and her baby. In this context, the value of this study is to demonstrate that performing an ultrasound as close to the birth as possible could allow for a more reliable estimation of fetal weight and better detection of macrosomia in order to avoid unnecessary procedures.\n\nThe investigators hypothesize that fetal weight estimation is more accurate when performed within 24 hours prior to delivery. When the assessment is conducted earlier, it inherently assumes a constant fetal growth rate until birth, which may not reflect actual growth patterns. A more precise estimation of birth weight could improve clinical decision-making and optimize maternal and neonatal care, potentially reducing unnecessary interventions such as labor induction or cesarean delivery.",[28,29],"Macrosomia","Fetal Weight",[28,31,32],"Fetal weight","Ultrasound","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2026-04-08",{"date":41,"type":22},"2028-09-01",{"name":43,"class":44},"Centre Hospitalier Henri Duffaut - Avignon","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100641882","ps-ivg--psychosocial-determinants-of-late-term-abortions-14-16-weeks-gestation-at-avignon-hospital-100641882","NCT07650071","PS IVG : Psychosocial Determinants of Late-term Abortions (14-16 Weeks' Gestation) at Avignon Hospital","PS IVG","Inclusion Criteria:\n\n* Patient aged ≥ 18 years\n* Pregnancy ≥ 14 weeks' gestation\n* Patient attending Avignon Hospital for a surgical abortion\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Medical abortion (non-surgical means of abortion)\n* Ectopic pregnancy\n* Inability to complete the questionnaire\n* Patients under legal protection measures (guardianship, curatorship, or court-ordered protection)",{"count":54,"type":22},30,[25],"Abortion is a fundamental right for women in France, where the legal time limit was extended from 14 to 16 weeks' gestation. This extension allows women, whose psychosocial determinants are poorly known, and who face various obstacles (personal, administrative, medical, or other), to access abortion. However, it may also expose them to psychological troubles and difficulties in accessing healthcare. This study aims to identify the psychosocial determinants and disruptions in the primary care pathway associated with late abortions (≥14 weeks' gestation \\[WG\\]) in order to propose preventive actions, particularly regarding contraception, screening, and referral, directly applicable in general practice.",[58,59],"Psychosocial Health","Abortion","NOT_YET_RECRUITING","2026-06-10",{"date":36,"type":37},{"date":34,"type":22},{"date":65,"type":22},"2027-09-15",{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":19,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":45},"100576723","evaluation-of-a-prehabilitation-protocol-using-adapted-physical-activity-apa-for-multiple-myeloma-patients-eligible-for-intensive-autologous-stem-cell-transplantation-treatment-100576723","NCT06789003","Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment","Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment (PREHAB-APA)","PREHAB-APA","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* CML patient in chronic phase, eligible for oral therapy.\n* Diagnosis of multiple myeloma.\n* Patient eligible for autologous stem cell transplantation.\n* Patient capable to read, understand and complete a questionnaire in french.\n* WHO less than or equal to 2.\n* Patient affiliated with french social security.\n* Patient with a medical prescription for APA.\n\nExclusion Criteria:\n\n* Patient with previous cancer within the previous 3 years (except basal cell and squamous cell skin cancers, carcinomas in situ of any type that have been previously resected, and stable prostate or breast cancers more than 3 years old and undergoing adjuvant hormone therapy).\n* Medical contraindications to APA (heart failure, angina, unbalanced hypertension, bone metastases, severe osteoporosis, etc.)\n* Sensory or motor neuropathy.\n* Patient deprived of liberty, under guardianship or curatorship.\n* Patient considered socially or psychologically unfit to be enrolled in a study.","ALL",{"count":77,"type":22},120,[25],"Adapted physical activity for patients with haematological malignancies generally has positive effects on quality of life, fatigue and physical condition. However, some studies show little or no effect.\n\nThis may be explained by inefficient protocols, but also by low rates of patient acceptability regarding the proposed exercises.\n\nThe multiplicity of APA protocols and the fluctuation of their results mean that validity, methodology and effects on patients need to be verified before they can be considered for implementation in healthcare services. A program must prove its feasibility, but patients must also adhere to it.\n\nAcceptability can be measured by adherence, which represents the number of validated sessions in relation to the number of planned sessions, and by attrition, which corresponds to the number of stops or drop-outs for any reason. The various APA programs offered in the context of intensive auto or allograft treatment are limited, notably by adherence, which can fall by as much as 24%, and attrition, which can be as high as 67%. Optimization of the proposed exercises and follow-up methods is therefore necessary in order to propose an APA program that will be feasible, effective and acceptable to a maximum number of patients.\n\nTo meet these objectives for patients with multiple myeloma eligible for autologous stem cell transplantation, the protocol for this study took into consideration the various recommendations of previous publications and the guidelines from HAS (French National Authority for Health).\n\nThe ultimate goal of this study is to validate, in terms of effectiveness and acceptability, the methodology and in particular the use of new specific tools for optimizing an APA program. It will subsequently be offered to all patients with multiple myeloma eligible for autologous stem cell transplantation, independently of their age or physical condition, while respecting their rhythm and physical condition.",[81],"Multiple Myeloma",[83,84,85,86],"Adapted Physical Activity","Autologous stem cell transplantation","Quality of Life","Fatigue","2026-03-02",{"date":89,"type":37},"2026-03-03",{"date":91,"type":37},"2025-02-10",{"date":93,"type":22},"2028-02-28",{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":75,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":45},"100522452","evaluation-of-advanced-practice-nurses-management-of-patients-with-chronic-myeloid-leukemia-100522452","NCT06082804","Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia","IPA-LMC","Inclusion Criteria:\n\n* Age ≥ 18 years old.\n* CML patient in chronic phase, eligible for oral therapy.\n* Newly diagnosed CML and\u002For initiating oral therapy :\n\n  * Patient changing treatment for non-response or loss of therapeutic response or toxicities, on the condition that these toxicities are resolved or grade I maximum at the time of inclusion.\n  * Newly start of oral therapy.\n* Patient eligible to a follow-up by an advanced practice nurse.\n* Patient capable to understand french and complete a questionnaire.\n\nExclusion Criteria:\n\n* Patient that had a follow-up \\> 3 months by an advanced practice nurse for CML before inclusion.\n* Patient changing treatment for toxicities, if these toxicities are still \\> grade I at inclusion.\n* Patient enrolled in another interventional research protocol for CML.\n* Pregnant women.\n* Patient under legal protection, deprived of liberty or unable to be included in a research protocol.",{"count":103,"type":22},60,[25],"Chronic Myeloid Leukemia (CML) affects 820 people per year in France (2018), half of them are older than 60 years old.\n\nTyrosine Kinase Inhibitors (TKI) are new kind of targeted therapy whose efficiency allow for a high rate of complete molecular response, leading to a disruption of treatment under certain conditions.\n\nOptimizing CML treatment is a major concern, particularly for adverse events management, treatment compliance and therapeutic response. Multiple studies demonstrated that grade ≤ II adverse events are most likely to be under reported by patients and clinicians. Although these adverse events are mostly reported by clinical examination, needing minimal treatment. These toxicities could alter daily and domestic living activities, potentially impacting treatment compliance and therapeutic response. Therefore, early detection of these adverse events is a major challenge for the prognosis and care of CML.\n\nThe Advanced Practice Nurse (APN), a new health care professional, acquired the skills needed to independently follow, manage and care the patients with medical approvals.\n\nAt international level, many studies, in oncology and in others domains, have been done to demonstrate the added value of the APN, particularly in improving patient's quality of life, management, care of drug-induced adverse events and treatment compliance.\n\nIn France, because of the recentness of the profession, only few studies were have been conducted. The goal of this study is to demonstrate the benefit of APN in clinical follow-up, quality of life, treatment compliance, and therapeutic response of CML patients. These effects could be managed thanks to early detection and management of ≤ grade II adverse events during consultation, in partnership with the patients, and in collaborative working.",[107],"Chronic Myelogenous Leukemia - Chronic Phase",[109,110,111],"Advanced Practice Nursing","Quality of life","Adverse event",{"date":113,"type":37},"2026-03-04",{"date":115,"type":37},"2023-11-29",{"date":117,"type":22},"2027-12",{"name":43,"class":44},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":75,"minAge":19,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100579288","short-term-effects-of-osteopathic-manipulations-on-heart-rate-variability-in-lung-cancer-patients---a-randomized-pilot-study-100579288","NCT06822348","Short-term Effects of Osteopathic Manipulations on Heart Rate Variability in Lung Cancer Patients - A Randomized Pilot Study","Short-term Effects of Osteopathic Manipulations on Heart Rate Variability in Lung Cancer Patients - A Randomized Pilot Study (OSTEOCAN2)","Inclusion Criteria:\n\n* Patient with stage 4 lung cancer.\n* WHO stage ≤ to 2.\n* Dyspnea grade ≤ 2 on the mMRC scale (modified Medical Research Council)\n* Patient undergoing chemotherapy for the first time\n* Patient with less than 5% artifact rate during rMSSD measurement.\n* Patient with SDNN less than 70 ms.\n* Voluntary patient who has signed the informed consent form.\n* No contraindications to osteopathic manipulation.\n\nExclusion Criteria:\n\n* Patient with unilateral or bilateral vagotomy.\n* Patient with cardiac arrhythmia.\n* Patient undergoing treatment influencing cardiac rhythm (anti-arrhythmic drugs, beta-blockers, etc.)\n* Patient with relapsed cancer already treated with chemotherapy.",{"count":127,"type":22},80,[25],"In France, the number of new cancer cases each year is rising steadily, while the number of deaths, although falling, is still around 157,000, including 23,000 from lung cancer alone. According to the French National Cancer Institute, there are three main methods of treating cancer: chemotherapy, radiotherapy and surgery. In recent years, new therapies have been developed, notably with the advent of immunotherapy and targeted therapies. On the other hand, although non-medical interventions (NMIs) such as osteopathy are recognized as improving the quality of life of cancer patients, there has been little research into their contribution when combined with conventional therapies.\n\nStudies have shown a link between the vagus nerve and cancer. Through its actions, the vagus nerve regulates homeostasis and immunity at local and regional levels, reducing systemic inflammation but maintaining local inflammation, which has an anti-tumour effect. At the same time, vagus nerve stimulation increases heart rate variability, which, when increased, is associated with improved vital prognosis in cancer patients. This stimulation can be achieved using a number of common, non-invasive osteopathic techniques.\n\nTo date, no study has shown an objective and definitive link between vagus nerve stimulation and improved vital prognosis. However, several studies show that vagus nerve activity may be related to prognosis in cancer patients through regulation of HRV and possibly inflammation. Osteopathic manipulation to stimulate the vagus nerve could therefore have an effect on HRV. Improved HRV could therefore indirectly improve the prognosis of cancer patients. The first step is to test this clinical hypothesis: does osteopathic manipulation stimulate the vagus nerve in cancer patients? This will be done by measuring heart rate variability using rMSSD, the metric most representative of vagal tone.\n\nThis randomized single-center pilot study will investigate the short-term effect of vagus nerve stimulation using osteopathic techniques on heart rate variability in lung cancer patients. Our hypothesis is that stimulation of the vagus nerve by gentle, non-invasive osteopathic manipulation would increase vagal tone and therefore improve HRV and quality of life in the short term, but also reduce anxiety experienced at the time of chemotherapy.",[131],"Lung Cancer",[133,134,135],"osteopathy","heart rate variability","quality of life","2026-01-08",{"date":138,"type":37},"2026-01-09",{"date":140,"type":22},"2026-02-01",{"date":142,"type":22},"2027-04-01",{"name":43,"class":44},""]